Roque on Vice Ganda's vaccine remark: Magtiwala sa eksperto, huwag sa komedyante

 By Deighton Acuin and Archie Villaflores

PHOTO: Manila Bulletin

If the public will not heed experts’ advice on coronavirus vaccines, then who should they trust about it? For presidential spokesperson Harry Roque, definitely not the comedians.

Even he did not mention who he was referring, Roque appears to be responding to an earlier tweet of Kapamilya comedian Vice Ganda.

Last January 12, Vice Ganda tweeted that Filipinos are known for being “choosy” in detergent brands for laundry used and what more on the vaccines they want to be injected with.

The comedian made the tweet after Roque said the Filipinos cannot afford of being “choosy” on COVID-19 vaccines if readily made available for use.

But in an apparent reply to Vice’s tweet, Roque said during his Monday Palace press briefing that it is wrong to compare vaccines from laundry soaps as he noted that three separate groups of vaccine experts are involved in the country’s vaccine screening process.

“Mali naman na ikumpara ang bakuna sa sabong panlaba. Ang katunayan po, wala nang supply na ganun karami. Nag-aagawan nga po tayo sa 18% na available supply. Pangalawa, hindi lang naman po ito gagamitin para sa damit. Kaya nga po hindi lang isa, hindi lang dalawa, kundi taltlong grupo pa ng eksperto ang mag-susuri kung ang mga bakuna ay ligtas at epektibo,” Roque said.

“Kung hindi naman po natin pagtitiwalaan ang mga experts…sino ang ating pagtitiwalaan? Siguro po hindi mga komedyante,” he added.

In the same conference, Roque reminded the public not to rush of believing social media posts, particularly those from politicians aspiring for upcoming 2022 national polls.

“Malapit na po kasi ang eleksyon. Isang taon at kalahati (nalang). Kaya ang ang mga desperado na gustong mahalal ng taumbayan, kung anu-anong fake news ang pinapakalat. Huwag po tayong maging biktima sa kanila,” Roque said.

The government secured 25 million doses from Chinese pharmaceutical firm Sinovac, 17 million doses from British pharmaceutical firm AstraZeneca, and 30 million doses from India’s Covovax.